Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.30 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.30 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669074 | 0.88 | CD274 (0.33) | CAMKK1CAMKK2 | |
| SCHEMBL5432203 | 0.79 | PDE4D (0.36) | — | |
| SCHEMBL12502230 | 0.78 | MAPK14 (0.39) | PRKAA1 | |
| SCHEMBL12501938 | 0.78 | ALOX5AP (0.45) | CAMKK1CAMKK2 | |
| SCHEMBL20083145 | 0.77 | CAMKK1 (0.30) | CAMKK1CAMKK2 | |
| SCHEMBL3555173 | 0.76 | — | — | |
| SCHEMBL6669852 | 0.74 | CAMKK2 (0.33) | CAMKK1CAMKK2 | |
| SCHEMBL1290293 | 0.73 | SMN1; SMN2 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4962760 | 0.72 | CYP1A2 (0.33) | — | |
| SCHEMBL12502443 | 0.72 | PIK3CA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227096-B1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | SATO PHARMA (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6525066-B2 | Bactericides; side effect reduction | SATO PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | SATO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| EP-1227096-A1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | Sato Pharmaceutical Co. Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | IL4I1, TLR5, IFNG | CAMKK1 3356/4885CAMKK2 3507/4885PRKAB2 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.